RxDoctor Payments Data

Sunil Ramrakhiani, MD

Gastroenterology · Fort Wayne, INNPI 1407805849

Payments from drug & device makers

$10,886in general payments, 2019–2025

Across 512 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Olympus Corporation Of The Americas$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$467
  • Nestle Healthcare Nutrition Inc.$335
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$300
  • Lilly USA, LLC$191
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$6,886100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,886 in reported general payments places this provider in the 75th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$106,442
Medicare patients
444
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid12$114,720
Humira(Cf) PenAdalimumab14$99,617
CreonLipase/Protease/Amylase17$79,414
LinzessLinaclotide18$14,798
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl496$7,091
Ursodiol26$4,531
Pantoprazole Sodium330$3,014
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl161$2,207
Omeprazole63$1,520
Famotidine110$1,415
Sucralfate45$1,263
Ondansetron OdtOndansetron15$465
Dicyclomine Hcl16$234
Spironolactone17$171
Furosemide15$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$95$114,72012 claims
AbbVieCreon, Linzess$4,137$94,21235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →